Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
RenovoRx, Inc. RNXT
$2.50
-$0.08 (-3.10%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
27271137.00000000
-
week52high
5.75
-
week52low
1.50
-
Revenue
0
-
P/E TTM
-3
-
Beta
0.00000000
-
EPS
-1.00000000
-
Last Dividend
0.00000000
-
Next Earnings Date
02 мар 2023 г. в 13:30
Описание компании
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Roth Capital | Buy | 01 ноя 2021 г. | |
| Maxim Group | Buy | 06 окт 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Marton Laurence | D | 0 | 25438 | 03 ноя 2022 г. |
| Marton Laurence | A | 25438 | 25438 | 03 ноя 2022 г. |
| RYAN UNA S | A | 25099 | 25099 | 01 окт 2022 г. |
| Marton Laurence | A | 25099 | 25099 | 01 окт 2022 г. |
| Diamond David | A | 25099 | 25099 | 01 окт 2022 г. |
| Macfarlane K. Angela | A | 25099 | 25099 | 01 окт 2022 г. |
| Nelms Angela | A | 274230 | 274230 | 19 сент 2022 г. |
| Agah Ramtin | A | 6477 | 5182 | 07 июн 2022 г. |
| Bagai Shaun | A | 251557 | 5500 | 19 мая 2022 г. |
| Agah Ramtin | A | 975000 | 975000 | 16 мар 2022 г. |
Новостная лента
RenovoRx to Present at the Sequire Biotechnology Virtual Conference on February 2, 2023
Business Wire
25 янв 2023 г. в 08:30
LOS ALTOS, Calif.--( BUSINESS WIRE )--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, today announced that Shaun Bagai, Chief Executive Officer, is scheduled to present virtually at the Sequire Biotechnology Conference on Thursday, February 2, 2023 at 4 p.m. (ET). To register for the event, visit the Sequire Biotechnology Conference website.